Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial.

Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial. Stroke. 2013 Oct; 44(10):2688-93.

View in: PubMed

subject areas

Aged
Atherosclerosis
Brain Ischemia
Delayed-Action Preparations
Female
Follow-Up Studies
Humans
Hypolipidemic Agents
Lipoproteins, HDL
Male
Metabolic Syndrome
Middle Aged
Niacin
Simvastatin
Stroke
Thrombosis
Triglycerides

authors with profiles

Larry Goldstein